Abstract
Despite recent advances in treatment of head and neck cancer, survival has not improved as expected. Bcl-2 family proteins play important role in regulating apoptosis. Recently, newer molecules have been developed for inhibition of Bcl-2 related proteins. We, herein aim to discuss the importance of Bcl-2 family proteins to the development of head and neck cancer and how the targeted-therapy for inhibition of Bcl-2 and related proteins, based on new drugs and recent patents, could improve the efficacy of the systemic therapy.
Keywords: Anticancer drugs, apoptosis, Bcl-2 family proteins, head and neck cancer, patents, targeted-therapy, squamous cell carcinoma, HNSCC, human papillomavirus (HPV) infection, radiochemotherapy, EGFR, FADD, tumorigenesis, Bcl-xL, Mcl-1, BH3-only, Bim, Puma, STAT3, fluoropyrimidines, VEGF, angiogenesis, TERT, Bortezomib, Human papillo-mavirus proteins, Azadirachta indica, gefitinib, Epigallocatechin-3 gallate, EGCG, Apogossypolone, Streptomyces, Chelidonium majus, obatoclax, BIE, BBF
Recent Patents on Anti-Cancer Drug Discovery
Title: Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Volume: 6 Issue: 1
Author(s): Lucas V. dos Santos and Andre L. Carvalho
Affiliation:
Keywords: Anticancer drugs, apoptosis, Bcl-2 family proteins, head and neck cancer, patents, targeted-therapy, squamous cell carcinoma, HNSCC, human papillomavirus (HPV) infection, radiochemotherapy, EGFR, FADD, tumorigenesis, Bcl-xL, Mcl-1, BH3-only, Bim, Puma, STAT3, fluoropyrimidines, VEGF, angiogenesis, TERT, Bortezomib, Human papillo-mavirus proteins, Azadirachta indica, gefitinib, Epigallocatechin-3 gallate, EGCG, Apogossypolone, Streptomyces, Chelidonium majus, obatoclax, BIE, BBF
Abstract: Despite recent advances in treatment of head and neck cancer, survival has not improved as expected. Bcl-2 family proteins play important role in regulating apoptosis. Recently, newer molecules have been developed for inhibition of Bcl-2 related proteins. We, herein aim to discuss the importance of Bcl-2 family proteins to the development of head and neck cancer and how the targeted-therapy for inhibition of Bcl-2 and related proteins, based on new drugs and recent patents, could improve the efficacy of the systemic therapy.
Export Options
About this article
Cite this article as:
V. dos Santos Lucas and L. Carvalho Andre, Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980042
DOI https://dx.doi.org/10.2174/157489211793980042 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Cationic Liposomes as In Vivo Delivery Vehicles
Current Medicinal Chemistry Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues
Current Topics in Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry Current Targets for Anticancer Drug Discovery
Current Drug Targets Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Immunological and Translational Aspects of Glycolytic Metabolism in Various Human Tumor Entities
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)